Jikun Li

Jikun Li

Auto-generated profile, based on publicly available information

Jikun Li

Institute of Chemistry, Chinese Academy of Sciences, 100190 Beijing, China

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
XFXinxin Feng
Xinxin Feng
WZWei Zhu
Wei Zhu
LSLici A. Schurig-Briccio
Lici A. Schurig-Briccio
SLSteffen Lindert
Steffen Lindert
CSCarolyn Shoen
Carolyn Shoen
EOEric Oldfield
Eric Oldfield
There is a growing need for new antibiotics. Compounds that target the proton motive force (PMF), uncouplers, represent one possible class of compounds that might be developed because they are already used to treat parasitic infections, and there is interest in their use for the treatment of other diseases, such as diabetes. Here, we tested a series of compounds, most with known antiinfective activity, for uncoupler activity. Many cationic amphiphiles tested positive, and some targeted isoprenoid biosynthesis or affected lipid bilayer structure. As an example, we found that clomiphene, a recently discovered undecaprenyl diphosphate synthase inhibitor active against Staphylococcus aureus, is an uncoupler. Using in silico screening, we then found that the anti-glioblastoma multiforme drug lead vacquinol is an inhibitor of Mycobacterium tuberculosis tuberculosinyl adenosine synthase, as well as being an uncoupler. Because vacquinol is also an inhibitor of M. tuberculosis cell growth, we used similarity searches based on the vacquinol structure, finding analogs with potent (∼0.5–2 μg/mL) activity against M. tuberculosis and S. aureus. Our results give a logical explanation of the observation that most new tuberculosis drug leads discovered by phenotypic screens and genome sequencing are highly lipophilic (logP ∼5.7) bases with membrane targets because such species are expected to partition into hydrophobic membranes, inhibiting membrane proteins, in addition to collapsing the PMF. This multiple targeting is expected to be of importance in overcoming the development of drug resistance because targeting membrane physical properties is expected to be less susceptible to the development of resistance.

3 June 2020 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
VOVictoria F. Oswald
Victoria F. Oswald
JLJustin L. Lee
Justin L. Lee
SBSaborni Biswas
Saborni Biswas
AWAndrew C. Weitz
Andrew C. Weitz
KMKaustuv Mittra
Kaustuv Mittra
ABAndrew Borovik
Andrew Borovik

19 February 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
WWWeixue Wang
Weixue Wang
KWKe Wang
Ke Wang
YLYi-Liang Liu
Yi-Liang Liu
JNJoo-Hwan No
Joo-Hwan No
JLJikun Li
Jikun Li
EOEric Oldfield
Eric Oldfield
We have investigated the mechanism of action of Aquifex aeolicus IspH [E-4-hydroxy-3-methyl-but-2-enyl diphosphate (HMBPP) reductase], together with its inhibition, using a combination of site-directed mutagenesis ( K M , V max ), EPR and 1 H, 2 H, 13 C, 31 P, and 57 Fe-electron-nuclear double resonance (ENDOR) spectroscopy. On addition of HMBPP to an (unreactive) E126A IspH mutant, a reaction intermediate forms that has a very similar EPR spectrum to those seen previously with the HMBPP “parent” molecules, ethylene and allyl alcohol, bound to a nitrogenase FeMo cofactor. The EPR spectrum is broadened on 57 Fe labeling and there is no evidence for the formation of allyl radicals. When combined with ENDOR spectroscopy, the results indicate formation of an organometallic species with HMBPP, a π / σ “metallacycle” or η 2 -alkenyl complex. The complex is poised to interact with H + from E126 (and H124) in reduced wt IspH, resulting in loss of water and formation of an η 1 -allyl complex. After reduction, this forms an η 3 -allyl π -complex (i.e. containing an allyl anion) that on protonation (at C2 or C4) results in product formation. We find that alkyne diphosphates (such as propargyl diphosphate) are potent IspH inhibitors and likewise form metallacycle complexes, as evidenced by 1 H, 2 H, and 13 C ENDOR, where hyperfine couplings of approximately 6 MHz for 13 C and 10 MHz for 1 H, are observed. Overall, the results are of broad general interest because they provide new insights into IspH catalysis and inhibition, involving organometallic species, and may be applicable to other Fe 4 S 4 -containing proteins, such as IspG.

4 March 2020 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
JLJikun Li
Jikun Li
HLHsuan-Jen Liao
Hsuan-Jen Liao
YTYijie Tang
Yijie Tang
JHJhih-Liang Huang
Jhih-Liang Huang
LCLide Cha
Lide Cha
YGYisong Guo
Yisong Guo

7 June 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
WWWeixue Wang
Weixue Wang
JLJikun Li
Jikun Li
KWKe Wang
Ke Wang
CHCancan Huang
Cancan Huang
YZYong Zhang
Yong Zhang
EOEric Oldfield
Eric Oldfield
We report the results of a series of chemical, EPR, ENDOR, and HYSCORE spectroscopic investigations of the mechanism of action (and inhibition) of GcpE,E-1-hydroxy-2-methyl-but-2-enyl-4-diphosphate (HMBPP) synthase, also known as IspG, an Fe4S4cluster-containing protein. We find that the epoxide of HMBPP when reduced by GcpE generates the same transient EPR species as observed on addition of the substrate, 2-C-methyl-D-erythritol-2, 4-cyclo-diphosphate. ENDOR and HYSCORE spectra of these transient species (using2H,13C and17O labeled samples) indicate formation of an Fe-C-H containing organometallic intermediate, most likely a ferraoxetane. This is then rapidly reduced to a ferracyclopropane in which the HMBPP product forms anη2-alkenylπ- (orπ/σ) complex with the 4th Fe in the Fe4S4cluster, and a similar “metallacycle” also forms between isopentenyl diphosphate (IPP) and GcpE. Based on this metallacycle concept, we show that an alkyne (propargyl) diphosphate is a good (Ki ∼ 300 nM) GcpE inhibitor, and supported again by EPR and ENDOR results (a13C hyperfine coupling of ∼7 MHz), as well as literature precedent, we propose that the alkyne forms anotherπ/σmetallacycle, anη2-alkynyl, or ferracyclopropene. Overall, the results are of broad general interest because they provide new mechanistic insights into GcpE catalysis and inhibition, with organometallic bond formation playing, in both cases, a key role.

1 May 2014 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
NSNa Shang
Na Shang
QLQian Li
Qian Li
TKTzu-Ping Ko
Tzu-Ping Ko
HCHsiu-Chien Chan
Hsiu-Chien Chan
JLJikun Li
Jikun Li
RGRey-Ting Guo
Rey-Ting Guo
Trypanosomatid parasites are the causative agents of many neglected tropical diseases and there is currently considerable interest in targeting endogenous sterol biosynthesis in these organisms as a route to the development of novel anti-infective drugs. Here, we report the first x-ray crystallographic structures of the enzyme squalene synthase (SQS) from a trypanosomatid parasite, Trypanosoma cruzi, the causative agent of Chagas disease. We obtained five structures of T. cruzi SQS and eight structures of human SQS with four classes of inhibitors: the substrate-analog S-thiolo-farnesyl diphosphate, the quinuclidines E5700 and ER119884, several lipophilic bisphosphonates, and the thiocyanate WC-9, with the structures of the two very potent quinuclidines suggesting strategies for selective inhibitor development. We also show that the lipophilic bisphosphonates have low nM activity against T. cruzi and inhibit endogenous sterol biosynthesis and that E5700 acts synergistically with the azole drug, posaconazole. The determination of the structures of trypanosomatid and human SQS enzymes with a diverse set of inhibitors active in cells provides insights into SQS inhibition, of interest in the context of the development of drugs against Chagas disease. Chagas disease is caused by the protozoan parasite Trypanosoma cruzi and affects eight million individuals, primarily in Latin America. Currently there is no cure for chronic T. cruzi infections. Unlike humans, this parasite use a variety of sterols (e.g. ergosterol, 24-ethyl-cholesta-5,7,22-trien-3 beta ol, and its 22-dihydro analogs), rather than cholesterol in their cell membranes, so inhibiting endogenous sterol biosynthesis is an important therapeutic target. Here, we report the first structure of the parasite's squalene synthase, which catalyzes the first committed step in sterol biosynthesis, as well as the structures of a broad range of squalene synthase inhibitors active against the clinically relevant intracellular stages, opening the way to new approaches to treating this neglected tropical disease.